Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIP-AML22 pediatric de novo AML master protocol
NL-OMON53580Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine, etoposide, fludarabine, methotrexate, mitoxantrone and 3 more in acute myeloid leukemia (AML) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Event-free survival and Disease-free survival for consolidation randomization. Started Sep 2023; status: recruiting.
02
Drugs
cytarabineetoposidefludarabinemethotrexatemitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON53580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53580.